MULTIPLE MYELOMA RESEARCH FOUNDATION
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1998-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.themmrf.org/
Clinical Trials
3
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
MMRF CureCloud Research Initiative
- Conditions
- Multiple Myeloma
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Multiple Myeloma Research Foundation
- Target Recruit Count
- 1105
- Registration Number
- NCT03657251
- Locations
- ๐บ๐ธ
Multiple Myeloma Research Foundation, Norwalk, Connecticut, United States
๐บ๐ธWashington University Medical Campus, Saint Louis, Missouri, United States
๐บ๐ธHackensack University Medical Center, Hackensack, New Jersey, United States
MMRF Molecular Profiling Protocol
- Conditions
- Plasma MalignancyMultiple Myeloma
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Multiple Myeloma Research Foundation
- Target Recruit Count
- 1000
- Registration Number
- NCT02884102
- Locations
- ๐บ๐ธ
Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States
๐บ๐ธCity of Hope, Duarte, California, United States
๐บ๐ธUCSF Medical Center, San Francisco, California, United States
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile
- Conditions
- Multiple Myeloma
- First Posted Date
- 2011-10-19
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Multiple Myeloma Research Foundation
- Target Recruit Count
- 1154
- Registration Number
- NCT01454297
- Locations
- ๐บ๐ธ
Mayo Clinic Campus in Scottsdale, AZ, Scottsdale, Arizona, United States
๐บ๐ธUC San Diego Moores Cancer Center, San Diego, California, United States
๐บ๐ธSharp Health Care, San Diego, California, United States
News
MMRF's Horizon Trial Program Enrolls First Patient to Optimize Myeloma Treatment
The Multiple Myeloma Research Foundation (MMRF) has initiated its Horizon Clinical Trials Program, enrolling the first patient in a study of relapsed and refractory myeloma.